Financial Performance - The company reported a revenue of ¥528,042,409.63 for the first half of 2025, a decrease of 16.38% compared to ¥631,461,882.24 in the same period last year [8] - The net profit attributable to shareholders was -¥775,820.00, reflecting a decline of 155.31% year-on-year [3] - Operating costs decreased by 17.55% to ¥441,091,432.86 [8] - Research and development expenses increased by 16.40% to ¥20,173,329.07 [8] Market Strategy - The company aims to enhance its core competitiveness through industry integration and improving its main business operations [4][9] - Focus on expanding overseas markets as a key growth driver [5][9] - Plans to establish three major platforms: medical products, medical services, and healthcare industry [5] Challenges and Responses - The decline in revenue is attributed to reduced engineering income and increased interest payments on convertible bonds [3][8] - The company is addressing slow domestic business growth and delayed receivables by intensifying international market expansion and improving accounts receivable collection [9] Future Outlook - The Egyptian medical consumables production base is expected to commence operations in Q4 2025 [5] - The management emphasizes the importance of maintaining a strong business foundation to achieve sustainable returns for investors [4][9]